ABOUT OUR RESEARCH
PreP and other Innovations in Biomedical Prevention
A strategy that involves the use of anti-HIV medications (also called antiretrovirals, or ARVs) by HIV-negative individuals to reduce the risk of HIV infection via sexual exposure. In 2012, the US Food and Drug Administration (FDA) approved the drug, Truvada, for daily oral use as PrEP. At HART, we are committed to understanding the impact of this new biomedical prevention strategy on both individuals and communities.
We are currently conducting two NIH-funded studies on this topic: one that focuses on developing public health messaging about PrEP that maximizes clear communication to potential users and another that works with a community-based health clinic to develop a PrEP Demonstration project in New York City. For more information about these studies, click on their individual project pages on the left.
Risk Taking and Decision Making
The other central focus of HART's work is to better understand the dynamics and determinants of risk behavior and risky decision-making. Through the integration of theoretical models and methods across disciplines, our work explores social, cognitive, affective, contextual, and biological factors that impact these processes.
Studies include NIH-funded investigations of the interaction between internal conflict and alcohol use in risk behaviors, a project examining the association between neuropsychological assessments of decision-making styles and HIV risk, and an experimental investigation of specific factors driving risk perception. For more information about these studies, click on the individual project pages on the left.